April 25, 2024- Vizient, Inc. hosted its inaugural Insight: Cell, Gene, and Specialty Pharmacy Symposium, bringing together leading healthcare providers, payers and manufacturers of high-cost, ultra-specialty pharmaceuticals along with other stakeholders to discuss the promise and unique challenges of the rapidly expanding market of cell, gene and other advanced therapies. The three-day meeting began April 8 in Atlanta.
To date, there are 22 ultra-specialty treatments approved in the U.S. with prices ranging from $450,000 to $4.25 million for a single dose treatment. Some estimates predict the market for these agents could reach $25 billion by 2026.